Swiss Life Asset Management’s Royalty Pharma RPRX Stock Holding History

Swiss Life Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Hold	0	–	–	–	376
2026 Q1	–	Sell	-117,145	Closed	-$4.53M	–	1599
2025 Q4	$4.53M	Buy	117,145 +2,888	+3%	+$110K	0.02%	430
2025 Q3	$4.03M	Buy	+114,257	New	+$4.14M	0.02%	445
2025 Q2	–	Sell	-251,880	Closed	-$8.34M	–	396
2025 Q1	$7.84M	Buy	251,880 +121,576	+93%	+$3.85M	0.06%	255
2024 Q4	$3.32M	Buy	130,304 +76,078	+140%	+$2.02M	0.02%	387
2024 Q3	$1.53M	Buy	54,226 +1,999	+4%	+$55.4K	0.02%	417
2024 Q2	$1.38M	Buy	+52,227	New	+$1.45M	0.02%	421
2023 Q3	–	Sell	-56,825	Closed	-$1.75M	–	640
2023 Q2	$1.75M	Hold	56,825	–	–	0.03%	504
2023 Q1	$2.05M	Buy	+56,825	New	+$2.11M	0.03%	489

Other funds holding RPRX

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Amundi Paris, France $413B AUM 44.57% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Swiss Life Asset Management's RPRX Position: Q2 2026 in Review

Swiss Life Asset Management held its Royalty Pharma (RPRX) position steady in Q2 2026 at 0 shares worth $7.64M. The position accounts for 0.03% of the portfolio, ranked #376.

Swiss Life Asset Management first reported a position in RPRX in Q1 2023 and has held it in 8 quarters since. The position peaked at $7.84M in Q1 2025. 434 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Swiss Life Asset Management held 0 shares of Royalty Pharma worth $7.64M as of Q2 2026.
Swiss Life Asset Management left its Royalty Pharma share count unchanged in Q2 2026.
Royalty Pharma made up 0.03% of Swiss Life Asset Management's portfolio in Q2 2026, its #376 holding.
Swiss Life Asset Management first reported a position in Royalty Pharma in Q1 2023 and has held it in 8 quarters since.
Swiss Life Asset Management's Royalty Pharma position peaked at $7.84M in Q1 2025.
434 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.